Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Sponsor: Exciva GmbH
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
Official title: Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants With Alzheimer's Disease Dementia
Key Details
Gender
All
Age Range
55 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2026-02-02
Completion Date
2029-02
Last Updated
2026-03-04
Healthy Volunteers
No
Interventions
EXV-802
Specified dose twice daily
Placebo
Specified dose twice daily
EXV-801
Specified dose twice daily
Locations (13)
Esperanza Clinical
Murrieta, California, United States
Josephson Wallack Munshower Neurology PC
Indianapolis, Indiana, United States
Precise Research Centers
Flowood, Mississippi, United States
Integrative Clinical Trials
Brooklyn, New York, United States
Manhattan Behavioral Medicine
New York, New York, United States
Insight Clinical Trials
Independence, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
The Memory Clinic
Bennington, Vermont, United States
Sunnybrook Health Sciences Centre
North York, Ontario, Canada
Baycrest Centre for Geriatric Care
North York, Ontario, Canada
Kawartha Centre
Peterborough, Ontario, Canada
Ontario Shores Centre for Mental Health Sciences
Whitby, Ontario, Canada
Scottish Brain Sciences
Edinburgh, Midlothian, United Kingdom